Straits Times Index
3,212.64 -6.36 (-0.20%) Nikkei
27,385.25 -34.36 (-0.13%) Hang Seng
19,915.68 -133.96 (-0.67%) FTSE 100
7,405.45 -94.15 (-1.26%) Bitcoin USD
27,540.72 -44.16 (-0.16%) CMC Crypto 200
597.33 -21.06 (-3.41%)
VRTX Jan 2024 410.000 call
| Previous close | 10.00 |
| Open | N/A |
| Bid | 3.40 |
| Ask | 10.90 |
| Strike | 410.00 |
| Expiry date | 2024-01-19 |
| Day's range | 10.00 - 10.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
- Motley Fool
Nasdaq Bear Market: 2 Growth Stocks to Buy That Keep Bucking the Trend
The past 15 months haven't been easy for growth stock investors. The Nasdaq Composite index has fallen a disappointing 25% since the beginning of 2022, making this an unusually long bear market. You don't need an economics degree to see that every bear market in history has been wiped away by subsequent recoveries.
- Zacks
Halozyme Therapeutics (HALO) Down 34.4% Since Last Earnings Report: Can It Rebound?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Motley Fool
This Cathie Wood Stock Could Nearly Double, According to Wall Street
One stock that could ride the market rally is CRISPR Therapeutics (NASDAQ: CRSP). This biotech is seeking to develop breakthrough therapies for difficult-to-treat illnesses using gene editing, and the company's focus in this area earned it a prominent place in the Ark Genomic Revolution ETF, an exchange-traded fund overseen by Cathie Wood. Wood isn't the only one on Wall Street who likes CRISPR.
